(Total Views: 520)
Posted On: 10/18/2020 1:31:27 PM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
YES, separating severe from critical for more detailed Interim analysis, could be the best decision of the year related to covid-19, leading to Leronlimab's approval. However, that would make the number of patients smaller each of these 2 Interim analyses, and thus, might not calculate out to improved p value? Am I missing something here?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)